Earnings Preview: Arcturus Therapeutics

Arcturus Therapeutics (NASDAQ:ARCT) is gearing up to announce its quarterly earnings on Tuesday, 2026-03-03. Here's a quick overview of what investors should know before the release.

Analysts are estimating that Arcturus Therapeutics will report an earnings per share (EPS) of $-0.82.

Anticipation surrounds Arcturus Therapeutics's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.

New investors should understand that while earnings performance is important, market reactions are often driven by guidance.

Past Earnings Performance

Last quarter the company beat EPS by $0.49, which was followed by a 1.25% drop in the share price the next day.

Here's a look at Arcturus Therapeutics's past performance and the resulting price change:

Quarter	Q3 2025	Q2 2025	Q1 2025	Q4 2024
EPS Estimate	-0.98	-0.96	-1.10	-0.49
EPS Actual	-0.49	-0.34	-0.52	-1.11
Price Change %	-1.25	30.73	2.33	-8.89

Market Performance of Arcturus Therapeutics's Stock

Shares of Arcturus Therapeutics were trading at $8.23 as of February 27. Over the last 52-week period, shares are down 46.22%. Given that these returns are generally negative, long-term shareholders are likely upset going into this earnings release.

All You Need to Know About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. It operates in one business segment, which includes all activities related to the discovery, development, and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC and LUNAR-CF. Its Vaccine candidates include LUNAR-FLU, KOSTAIVE XBB.1.5, KOSTAIVE, and Others.

Financial Insights: Arcturus Therapeutics

Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.

Revenue Challenges: Arcturus Therapeutics's revenue growth over 3 months faced difficulties. As of 30 September, 2025, the company experienced a decline of approximately -63.54%. This indicates a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.

Net Margin: Arcturus Therapeutics's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -95.02% net margin, the company effectively manages costs and achieves strong profitability.

Return on Equity (ROE): Arcturus Therapeutics's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of -5.9%, the company showcases efficient use of equity capital and strong financial health.

Return on Assets (ROA): Arcturus Therapeutics's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of -4.55%, the company showcases efficient use of assets and strong financial health.

Debt Management: Arcturus Therapeutics's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.12.

To track all earnings releases for Arcturus Therapeutics visit their earnings calendar on our site.

This article was generated by Benzinga's automated content engine and reviewed by an editor.